Alpine's Pipeline
We have a diverse pipeline of multi-targeted therapies in development for both inflammatory disease and oncology.
IMMUNO-ONCOLOGY
davoceticept (ALPN-202)
Conditional CD28 Costimulator and Dual PD-L1/CTLA-4 Inhibitor
Preclinical | Phase 1 | Phase 2 | Phase 3 |

Preclinical | Phase 1 | Phase 2 | Phase 3 |

Details
Commmercial Rights:

Supply Agreement:

Davoceticept is engineered to provide direct T cell costimulation and dual checkpoint inhibition to enable the immune system to mount a robust anti-tumor response.
We are currently enrolling NEON-1, a Phase 1 dose escalation and expansion study of davoceticept in patients with advanced malignancies (NCT04186637).
NEON-2, a Phase 1 combination study of davoceticept with KEYTRUDA® (pembrolizumab) in patients with advanced malignancies is active, not recruiting (NCT04920383).
INFLAMMATORY DISEASES
ALPN-303
Dual B Cell Cytokine Antagonist of BAFF and APRIL
Preclinical | Phase 1 | Phase 2 | Phase 3 |
Details
Commmercial Rights:

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.
We are currently enrolling in a Phase 1 study of ALPN-303 in healthy volunteers (NCT05034484). This study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303. Multiple dose levels will be tested to help assess ALPN-303’s potential for the treatment of inflammatory diseases.
Partnered Programs
acazicolcept (ALPN-101)
Dual CD28/ICOS Antagonist
Preclinical | Phase 1 | Phase 2 | Phase 3 |

Details
Partners:

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.
We are currently enrolling Synergy, a Phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.
Discovery Collaboration
Immunology
Preclinicals | Phase 1 | Phase 2 | Phase 3 |

Next Generation TCR T-cell Therapies
Preclinicals | Phase 1 | Phase 2 | Phase 3 |

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.